The current earnings forecast score of Kiora Pharmaceuticals Inc is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.000
Target Price
+351.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kiora Pharmaceuticals Inc
KPRX
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kiora Pharmaceuticals Inc's expected revenue for the next quarter?
Kiora Pharmaceuticals Inc's expected revenue is 1.50M.
What is Kiora Pharmaceuticals Inc's price target?
Analysts forecast that Kiora Pharmaceuticals Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 12.00.
How have Kiora Pharmaceuticals IncKPRX's recent earnings per share performed?
The market expectation was USD -0.58, while Kiora Pharmaceuticals IncKPRX's earnings per share (EPS) for the previous quarter was USD -1.56. EPS for the next quarter is expected at USD -0.62.
What is the analyst rating for Kiora Pharmaceuticals Inc?
Based on the ratings of Kiora Pharmaceuticals Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.